Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent

• US 10,322,173 B2
• Filed: 01/14/2015
• Issued: 06/18/2019
• Est. Priority Date: 01/15/2014
• Status: Active Grant

• Current Assignee: Wave Life Sciences Japan, Inc.
• Original Assignee: Shin Nippon Biomedical Laboratories Limited, Wave Life Sciences Japan, Inc.
• Inventors: Gemba, Takefumi, Nagata, Ryoichi
• Primary Examiner(s): Leavitt, Maria G
• Application Number:
  US15/111,797
• Publication Number:
  US 20160331835A1
• Time in Patent Office: 1,616 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 15/117 Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• CPC Class Codes: C12N 2310/17 Immunomodulatory nucleic acids
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/344 Position-specific modifications, e.g. on every purine, at the 3'-end

Abstract

Problem

To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect.

Solution

An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5′-X₁CpGX₂-3′ and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3′ end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3′ end and 5′ end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Claims

1. A method for treating an allergic reaction, comprising administering to a subject a composition comprising a therapeutically effective amount of the oligonucleotide

T^SPC^SPGACGTT^SPT^SPT^SPGACGTT^SPT^SPT^SPGACG^SPT^SPT,

wherein each ^SP represents an S type phosphorothioate linkage.

2. The method as claimed in claim 1, further comprising administering an anti-allergic agent.

3. A method for treating an allergic rhinitis, comprising administering to a subject a composition comprising a therapeutically effective amount of the oligonucleotide

T^SPC^SPGACGTT^SPT^SPT^SPGACGTT^SPT^SPT^SPGACG^SPT^SPT

wherein each ^SP represents an S type phosphorothioate linkage.